1. Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities
- Author
-
Ministry of Education, Youth and Sports (Czech Republic), Czech Science Foundation, Agencia Estatal de Investigación (España), Universidad Camilo José Cela, Chrienova, Z., Nepovimova, E., Andrys, R., Dolezal, R., Janockova, Jana, Muckova, Lubica, Fabova, L., Soukup, Ondrej, Oleksak, Patrik, Valisa, M., Korabecny, J., Marco-Contelles, José, Kuca, K., Ministry of Education, Youth and Sports (Czech Republic), Czech Science Foundation, Agencia Estatal de Investigación (España), Universidad Camilo José Cela, Chrienova, Z., Nepovimova, E., Andrys, R., Dolezal, R., Janockova, Jana, Muckova, Lubica, Fabova, L., Soukup, Ondrej, Oleksak, Patrik, Valisa, M., Korabecny, J., Marco-Contelles, José, and Kuca, K.
- Abstract
Twenty-four novel compounds bearing tetrahydroacridine and N-propargyl moieties have been designed, synthesised, and evaluated in vitro for their anti-cholinesterase and anti-monoamine oxidase activities. Propargyltacrine 23 (IC = 21 nM) was the most potent acetylcholinesterase (AChE) inhibitor, compound 20 (IC = 78 nM) showed the best inhibitory human butyrylcholinesterase (hBChE) profile, and ligand 21 afforded equipotent and significant values on both ChEs (human AChE [hAChE]: IC = 0.095 ± 0.001 µM; hBChE: IC = 0.093 ± 0.003 µM). Regarding MAO inhibition, compounds 7, 15, and 25 demonstrated the highest inhibitory potential towards hMAO-B (IC = 163, 40, and 170 nM, respectively). In all, compounds 7, 15, 20, 21, 23, and 25 exhibiting the most balanced pharmacological profile, were submitted to permeability and cell viability tests. As a result, 7-phenoxy-N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroacridin-9-amine hydrochloride (15) has been identified as a permeable agent that shows a balanced pharmacological profile [IC (hAChE) = 1.472 ± 0.024 µM; IC (hBChE) = 0.659 ± 0.077 µM; IC (hMAO-B) = 40.39 ± 5.98 nM], and consequently, as a new hit-ligand that deserves further investigation, in particular in vivo analyses, as the preliminary cell viability test results reported here suggest that this is a relatively safe therapeutic agent.
- Published
- 2022